 |
 |
PRESS RELEASE: Shamrock Structures to Provide Proteomics Services for Biopharmaceutical Company Thursday August 5, 9:03 am ET WOODRIDGE, Ill., Aug. 5 /PRNewswire/ -- Shamrock Structures of Woodridge, Ill., has signed an agreement with Intra-Cellular Therapies, Inc. (ITI), a New York City- based biopharmaceutical company, to provide integrated structural proteomics services. Under the agreement, Shamrock Structures will perform structure-activity relationship (SAR) co-crystallization, synchrotron data collection, and structure determination of an Intra-Cellular Therapies protein target to which inhibitors are bound. The agreement terms include an upfront fee and performance-based milestone payments. Additional terms of the agreement remain undisclosed. "We are very pleased to support Intra-Cellular Therapies' drug discovery efforts through Shamrock Structures' X-ray crystallography services," said Steve Schiltz, Shamrock's CEO. "Three dimensional structure determination of protein-inhibitor complexes will further our ability to develop potent and selective new drugs to treat depression, schizophrenia, Alzheimer's and Parkinson's disease," said Sharon Mates, Ph.D. founder, chairman, and CEO of Intra-Cellular Therapies, Inc. (ITI). Intra-Cellular Therapies, Inc. (ITI) is a privately held biopharmaceutical company developing novel drugs for depression, schizophrenia, Alzheimer's and Parkinson's disease, and other disorders of the central nervous system. The company is headquartered in the Audubon Biomedical Science & Technology Park in New York City. ( http://www.intracellulartherapies.com ) Shamrock Structures, LLC, based in Woodridge, Ill. ( http://www.shamrockstructures.com ) is a privately held, structural proteomics company that determines the three dimensional structures of proteins and protein complexes. The company offers integrated proteomics services and efficient access to X-ray synchrotron data collection, enabling pharmaceutical and biotechnology clients to decrease the time required to advance from protein targets to novel drug development. Source: Shamrock Structures, LLC SOURCE: Yahoo News (press release) http://biz.yahoo.com/prnews/040805/cgth003_1.html * * * ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn